HEADER HYDROLASE/HYDROLASE INHIBITOR 02-JUL-99 1QUR TITLE HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED TITLE 2 SYNTHETIC INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: HUMAN THROMBIN (ALPHA CHAIN); COMPND 3 CHAIN: L; COMPND 4 MOL_ID: 2; COMPND 5 MOLECULE: HUMAN THROMBIN (BETA CHAIN); COMPND 6 CHAIN: H; COMPND 7 MOL_ID: 3; COMPND 8 MOLECULE: BIVALENT INHIBITOR (BZA-2 HIRULOG); COMPND 9 CHAIN: I; COMPND 10 ENGINEERED: YES; COMPND 11 OTHER_DETAILS: 2-NAPHTHYLSULFONYL-GLU(NH-(CH2)3-CO-(GLY)4-ASN-GLY- COMPND 12 ASP-TYR-GLU-PRO-ILE-PRO-GLU-GLU-ALA-CYCLOHEXYLALANINE-(D)GLU)-(D)4- COMPND 13 AMIDINOPHENYLALANINE-PIPERIDIDE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 MOL_ID: 2; SOURCE 6 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 7 ORGANISM_COMMON: HUMAN; SOURCE 8 ORGANISM_TAXID: 9606; SOURCE 9 MOL_ID: 3; SOURCE 10 SYNTHETIC: YES; SOURCE 11 OTHER_DETAILS: THE INHIBITOR WAS CHEMICALLY SYNTHESIZED AS SOURCE 12 COMBINATION OF ORGANIC AND SOLID PHASE PEPTIDE SYNTHESIS. THE ACTIVE SOURCE 13 SITE BINDING PORTION IS DERIVED FROM THE SYNTHETICAL INHIBITOR SOURCE 14 NAPAP,THE SEQUENCE OF THE EXOSITE BINDING PORTION WAS DERIVED FROM SOURCE 15 THE NATURALLY OCCURING INHIBITOR HIRUDIN, ISOLATED FROM THE MEDICAL SOURCE 16 LEECH AND THE SYNTHETICALLY SYNTHESIZED EXOSITE INHIBITOR MDL-28, SOURCE 17 050. KEYWDS TRYPSIN LIKE SERINE PROTEASE, BLOOD COAGULATION, HYDROLASE-HYDROLASE KEYWDS 2 INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR M.RENATUS,T.STEINMETZER REVDAT 6 15-NOV-23 1QUR 1 DBREF LINK ATOM REVDAT 5 13-JUL-11 1QUR 1 VERSN REVDAT 4 24-FEB-09 1QUR 1 VERSN REVDAT 3 01-APR-03 1QUR 1 JRNL REVDAT 2 15-NOV-00 1QUR 3 ATOM REMARK REVDAT 1 14-OCT-99 1QUR 0 JRNL AUTH T.STEINMETZER,M.RENATUS,S.KUNZEL,A.EICHINGER,W.BODE, JRNL AUTH 2 P.WIKSTROM,J.HAUPTMANN,J.STURZEBECHER JRNL TITL DESIGN AND EVALUATION OF NOVEL BIVALENT THROMBIN INHIBITORS JRNL TITL 2 BASED ON AMIDINOPHENYLALANINES. JRNL REF EUR.J.BIOCHEM. V. 265 598 1999 JRNL REFN ISSN 0014-2956 JRNL PMID 10504391 JRNL DOI 10.1046/J.1432-1327.1999.00742.X REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 9.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 96.2 REMARK 3 NUMBER OF REFLECTIONS : 23360 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.209 REMARK 3 FREE R VALUE : 0.246 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 23360 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 22 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.03 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 53 REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : 0.3230 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2472 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 150 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 21.60 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.42700 REMARK 3 B22 (A**2) : 5.83900 REMARK 3 B33 (A**2) : -5.41200 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.76400 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 BOND ANGLES (DEGREES) : 1.525 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.457 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.086 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.310 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.082 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : CNS_TOPPAR:PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : NULL REMARK 3 TOPOLOGY FILE 1 : CNS_TOPPAR:WATER_REP.PARAM REMARK 3 TOPOLOGY FILE 2 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1QUR COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 06-JUL-99. REMARK 100 THE DEPOSITION ID IS D_1000009285. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 23-NOV-98 REMARK 200 TEMPERATURE (KELVIN) : 290 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU300 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA, CCP4 (SCALA) REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23412 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.980 REMARK 200 RESOLUTION RANGE LOW (A) : 9.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 93.4 REMARK 200 DATA REDUNDANCY : 2.300 REMARK 200 R MERGE (I) : 0.12800 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 4.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.98 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.09 REMARK 200 COMPLETENESS FOR SHELL (%) : 82.0 REMARK 200 DATA REDUNDANCY IN SHELL : 2.00 REMARK 200 R MERGE FOR SHELL (I) : 0.47600 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 53.65 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.65 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100 MM TRIS/HCL, 300-500 MM NACL, 22 REMARK 280 -32% (W/V) PEG 8000, MACRO SEEDING, TEMPERATURE 280K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 35.66000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.20500 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 35.66000 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 36.20500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE BIOLOGICAL ASSEMBLY OF ALPHA-THROMBIN CONSISTS OF THE REMARK 300 LARGE AND SMALL SUBUNIT, LINKED BY A DISULFID BRIDGE REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5570 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 13690 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -5.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: L, H, I REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 475 REMARK 475 ZERO OCCUPANCY RESIDUES REMARK 475 THE FOLLOWING RESIDUES WERE MODELED WITH ZERO OCCUPANCY. REMARK 475 THE LOCATION AND PROPERTIES OF THESE RESIDUES MAY NOT REMARK 475 BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 475 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE) REMARK 475 M RES C SSEQI REMARK 475 VAL H 149C REMARK 475 GLY H 149D REMARK 475 ABU I 48 REMARK 475 GLY I 49 REMARK 475 GLY I 50 REMARK 475 GLY I 51 REMARK 475 GLY I 52 REMARK 475 ASN I 53 REMARK 475 GLY I 54 REMARK 475 PRO I 60 REMARK 475 GLU I 61 REMARK 475 GLU I 62 REMARK 475 ALC I 64 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 LYS L 10 NZ REMARK 480 ARG L 14D CG CD NE CZ NH1 NH2 REMARK 480 ILE L 14K O CG1 CG2 CD1 REMARK 480 ARG H 50 NH1 NH2 REMARK 480 ARG H 75 CD NE CZ NH1 NH2 REMARK 480 LYS H 81 NZ REMARK 480 LYS H 87 CE NZ REMARK 480 LYS H 107 CE NZ REMARK 480 GLN H 151 CG CD OE1 NE2 REMARK 480 LYS H 236 CD CE NZ REMARK 480 GLN H 239 CB CG CD OE1 NE2 REMARK 480 LYS H 240 CG CD CE NZ REMARK 480 ASP H 243 C O CG OD1 OD2 REMARK 480 PHE H 245 OXT REMARK 480 DGL I 65 N CA C CB CG CD OE1 REMARK 480 DGL I 65 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 NE ARG H 101 O HOH H 335 2.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE L 7 -90.55 -130.26 REMARK 500 TYR H 60A 80.38 -153.96 REMARK 500 HIS H 71 -51.77 -127.27 REMARK 500 ASN H 78 -3.82 73.65 REMARK 500 ILE H 79 -61.82 -120.17 REMARK 500 GLU H 97A -53.17 -126.39 REMARK 500 ASN H 149B -15.84 56.93 REMARK 500 VAL H 149C 69.51 -100.30 REMARK 500 ASN H 205 19.55 59.43 REMARK 500 SER H 214 -71.93 -109.22 REMARK 500 ASP H 243 30.80 38.72 REMARK 500 GLN H 244 -11.30 -44.31 REMARK 500 ASN I 53 89.84 -154.06 REMARK 500 GLU I 62 3.71 -65.82 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN I OF BIVALENT INHIBITOR REMARK 800 (BZA-2 HIRULOG) DBREF 1QUR L 1B 14K UNP P00734 THRB_HUMAN 334 360 DBREF 1QUR H 16 245 UNP P00734 THRB_HUMAN 364 620 DBREF 1QUR I 47 65 PDB 1QUR 1QUR 47 65 SEQRES 1 L 27 ALA ASP CYS GLY LEU ARG PRO LEU PHE GLU LYS LYS SER SEQRES 2 L 27 LEU GLU ASP LYS THR GLU ARG GLU LEU LEU GLU SER TYR SEQRES 3 L 27 ILE SEQRES 1 H 257 ILE VAL GLU GLY SER ASP ALA GLU ILE GLY MET SER PRO SEQRES 2 H 257 TRP GLN VAL MET LEU PHE ARG LYS SER PRO GLN GLU LEU SEQRES 3 H 257 LEU CYS GLY ALA SER LEU ILE SER ASP ARG TRP VAL LEU SEQRES 4 H 257 THR ALA ALA HIS CYS LEU LEU TYR PRO PRO TRP ASP LYS SEQRES 5 H 257 ASN PHE THR GLU ASN ASP LEU LEU VAL ARG ILE GLY LYS SEQRES 6 H 257 HIS SER ARG THR ARG TYR GLU ARG ASN ILE GLU LYS ILE SEQRES 7 H 257 SER MET LEU GLU LYS ILE TYR ILE HIS PRO ARG TYR ASN SEQRES 8 H 257 TRP ARG GLU ASN LEU ASP ARG ASP ILE ALA LEU MET LYS SEQRES 9 H 257 LEU LYS LYS PRO VAL ALA PHE SER ASP TYR ILE HIS PRO SEQRES 10 H 257 VAL CYS LEU PRO ASP ARG GLU THR ALA ALA SER LEU LEU SEQRES 11 H 257 GLN ALA GLY TYR LYS GLY ARG VAL THR GLY TRP GLY ASN SEQRES 12 H 257 LEU LYS GLU THR TRP THR ALA ASN VAL GLY LYS GLY GLN SEQRES 13 H 257 PRO SER VAL LEU GLN VAL VAL ASN LEU PRO ILE VAL GLU SEQRES 14 H 257 ARG PRO VAL CYS LYS ASP SER THR ARG ILE ARG ILE THR SEQRES 15 H 257 ASP ASN MET PHE CYS ALA GLY TYR LYS PRO ASP GLU GLY SEQRES 16 H 257 LYS ARG GLY ASP ALA CYS GLU GLY ASP SER GLY GLY PRO SEQRES 17 H 257 PHE VAL MET LYS SER PRO PHE ASN ASN ARG TRP TYR GLN SEQRES 18 H 257 MET GLY ILE VAL SER TRP GLY GLU GLY CYS ASP ARG ASP SEQRES 19 H 257 GLY LYS TYR GLY PHE TYR THR HIS VAL PHE ARG LEU LYS SEQRES 20 H 257 LYS TRP ILE GLN LYS VAL ILE ASP GLN PHE SEQRES 1 I 19 00I ABU GLY GLY GLY GLY ASN GLY ASP TYR GLU PRO ILE SEQRES 2 I 19 PRO GLU GLU ALA ALC DGL MODRES 1QUR ALC I 64 ALA 2-AMINO-3-CYCLOHEXYL-PROPIONIC ACID HET 00I I 47 41 HET ABU I 48 6 HET ALC I 64 11 HET DGL I 65 9 HETNAM 00I N-[(1R)-1-(4-CARBAMIMIDOYLBENZYL)-2-OXO-2-PIPERIDIN-1- HETNAM 2 00I YLETHYL]-N~2~-(NAPHTHALEN-2-YLSULFONYL)-L-ALPHA- HETNAM 3 00I GLUTAMINE HETNAM ABU GAMMA-AMINO-BUTANOIC ACID HETNAM ALC 2-AMINO-3-CYCLOHEXYL-PROPIONIC ACID HETNAM DGL D-GLUTAMIC ACID HETSYN ABU GAMMA(AMINO)-BUTYRIC ACID FORMUL 3 00I C30 H35 N5 O6 S FORMUL 3 ABU C4 H9 N O2 FORMUL 3 ALC C9 H17 N O2 FORMUL 3 DGL C5 H9 N O4 FORMUL 4 HOH *150(H2 O) HELIX 1 1 PHE L 7 SER L 11 5 5 HELIX 2 2 THR L 14B TYR L 14J 1 9 HELIX 3 3 ALA H 55 CYS H 58 5 4 HELIX 4 4 PRO H 60B ASP H 60E 5 4 HELIX 5 5 THR H 60I ASN H 62 5 3 HELIX 6 6 ASP H 125 LEU H 130 1 9 HELIX 7 7 GLU H 164 ASP H 170 1 7 HELIX 8 8 LYS H 185 GLY H 186C 5 5 HELIX 9 9 LEU H 234 ASP H 243 1 10 SHEET 1 A 7 SER H 20 ASP H 21 0 SHEET 2 A 7 GLN H 156 PRO H 161 -1 N VAL H 157 O SER H 20 SHEET 3 A 7 LYS H 135 GLY H 140 -1 N GLY H 136 O LEU H 160 SHEET 4 A 7 PRO H 198 LYS H 202 -1 O PRO H 198 N THR H 139 SHEET 5 A 7 TRP H 207 TRP H 215 -1 N TYR H 208 O MET H 201 SHEET 6 A 7 GLY H 226 HIS H 230 -1 N PHE H 227 O TRP H 215 SHEET 7 A 7 MET H 180 ALA H 183 -1 O PHE H 181 N TYR H 228 SHEET 1 B 7 GLN H 30 ARG H 35 0 SHEET 2 B 7 GLU H 39 LEU H 46 -1 O GLU H 39 N ARG H 35 SHEET 3 B 7 GLN H 30 ARG H 35 -1 N VAL H 31 O ALA H 44 SHEET 4 B 7 LEU H 64 ILE H 68 -1 N LEU H 65 O PHE H 34 SHEET 5 B 7 LYS H 81 ILE H 90 -1 N LYS H 81 O ILE H 68 SHEET 6 B 7 ALA H 104 LEU H 108 -1 O LEU H 105 N TYR H 89 SHEET 7 B 7 TRP H 51 THR H 54 -1 N VAL H 52 O MET H 106 SHEET 1 C 2 LEU H 60 TYR H 60A 0 SHEET 2 C 2 LYS H 60F ASN H 60G-1 O LYS H 60F N TYR H 60A SSBOND 1 CYS L 1 CYS H 122 1555 1555 2.23 SSBOND 2 CYS H 42 CYS H 58 1555 1555 2.26 SSBOND 3 CYS H 168 CYS H 182 1555 1555 2.21 SSBOND 4 CYS H 191 CYS H 220 1555 1555 2.30 LINK CD 00I I 47 N ABU I 48 1555 1555 1.34 LINK C ABU I 48 N GLY I 49 1555 1555 1.35 LINK C ALA I 63 N ALC I 64 1555 1555 1.33 LINK C ALC I 64 N DGL I 65 1555 1555 1.34 CISPEP 1 SER H 36A PRO H 37 0 0.09 SITE 1 AC1 27 PHE H 34 LEU H 40 HIS H 57 ARG H 73 SITE 2 AC1 27 THR H 74 ARG H 75 TYR H 76 ILE H 82 SITE 3 AC1 27 MET H 84 ASN H 98 LEU H 99 ILE H 174 SITE 4 AC1 27 ASP H 189 ALA H 190 GLU H 192 SER H 195 SITE 5 AC1 27 TRP H 215 GLY H 216 GLY H 219 CYS H 220 SITE 6 AC1 27 GLY H 226 HOH H 248 HOH H 329 HOH I 66 SITE 7 AC1 27 HOH I 67 HOH I 71 HOH I 72 CRYST1 71.320 72.410 72.330 90.00 100.27 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.014021 0.000000 0.002541 0.00000 SCALE2 0.000000 0.013810 0.000000 0.00000 SCALE3 0.000000 0.000000 0.014051 0.00000